Katherine A Janeway

Summary

Affiliation: Massachusetts General Hospital
Country: USA

Publications

  1. ncbi Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group
    Katherine A Janeway
    Department of Pediatric Hematology Oncology, Dana Farber Children s Hospital Cancer Center, Boston, MA, USA
    Cancer 118:4597-605. 2012
  2. ncbi Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations
    Katherine A Janeway
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:314-8. 2011
  3. ncbi Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
    Katherine A Janeway
    Pediatric Oncology, Dana Farber Cancer Institute and Department of Medicine, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 52:767-71. 2009
  4. ncbi Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification
    Katherine A Janeway
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    Int J Cancer 127:2718-22. 2010
  5. ncbi Pediatric gastrointestinal stromal tumor
    Katherine A Janeway
    Department of Pediatric Oncology, Dana Farber Cancer Institute Children s Hospital Boston, Boston, Massachusetts, USA
    Semin Pediatr Surg 21:31-43. 2012
  6. ncbi Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
    Katherine A Janeway
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Children s Hospital Boston, Boston, MA, USA
    Lancet Oncol 11:670-8. 2010
  7. ncbi Treatment guidelines for gastrointestinal stromal tumors in children and young adults
    Katherine A Janeway
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Pediatr Hematol Oncol 34:S69-72. 2012
  8. ncbi Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors
    Katherine A Janeway
    Department of Medicine, Children s Hospital Boston, MA, USA
    Cancer Res 67:9084-8. 2007
  9. ncbi Modeling human osteosarcoma in the mouse: From bedside to bench
    Katherine A Janeway
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Division of Hematology Oncology, Children s Hospital Boston, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
    Bone 47:859-65. 2010

Detail Information

Publications9

  1. ncbi Outcome for adolescent and young adult patients with osteosarcoma: a report from the Children's Oncology Group
    Katherine A Janeway
    Department of Pediatric Hematology Oncology, Dana Farber Children s Hospital Cancer Center, Boston, MA, USA
    Cancer 118:4597-605. 2012
    ..The authors conducted a study evaluating the impact of age on prognosis in children and young adults with osteosarcoma enrolled on North American cooperative group trials...
  2. ncbi Defects in succinate dehydrogenase in gastrointestinal stromal tumors lacking KIT and PDGFRA mutations
    Katherine A Janeway
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    Proc Natl Acad Sci U S A 108:314-8. 2011
    ..Testing for germline mutations in SDH is recommended in patients with WT GIST. These findings highlight a potential central role of SDH dysregulation in WT GIST oncogenesis...
  3. ncbi Sunitinib treatment in pediatric patients with advanced GIST following failure of imatinib
    Katherine A Janeway
    Pediatric Oncology, Dana Farber Cancer Institute and Department of Medicine, Children s Hospital Boston, Boston, Massachusetts 02115, USA
    Pediatr Blood Cancer 52:767-71. 2009
    ..Sunitinib prolongs survival in adult patients with imatinib-resistant gastrointestinal stromal tumor (GIST). We report the experience with sunitinib in pediatric patients with advanced GIST following failure of imatinib...
  4. ncbi Strong expression of IGF1R in pediatric gastrointestinal stromal tumors without IGF1R genomic amplification
    Katherine A Janeway
    Department of Pediatric Hematology Oncology, Dana Farber Cancer Institute and Children s Hospital, Boston, MA 02115, USA
    Int J Cancer 127:2718-22. 2010
    ..Despite the absence of apparent genomic activation mechanisms accounting for overexpression, clinical study of IGF1R-directed therapies in pediatric WT GIST is warranted...
  5. ncbi Pediatric gastrointestinal stromal tumor
    Katherine A Janeway
    Department of Pediatric Oncology, Dana Farber Cancer Institute Children s Hospital Boston, Boston, Massachusetts, USA
    Semin Pediatr Surg 21:31-43. 2012
    ....
  6. ncbi Sequelae of osteosarcoma medical therapy: a review of rare acute toxicities and late effects
    Katherine A Janeway
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Children s Hospital Boston, Boston, MA, USA
    Lancet Oncol 11:670-8. 2010
    ....
  7. ncbi Treatment guidelines for gastrointestinal stromal tumors in children and young adults
    Katherine A Janeway
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Boston, MA 02215, USA
    J Pediatr Hematol Oncol 34:S69-72. 2012
    ..Guidelines for diagnostic evaluation and management of GIST in children are presented. The presented guidelines are based on clinical experience and data from case reports and case series...
  8. ncbi Pediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumors
    Katherine A Janeway
    Department of Medicine, Children s Hospital Boston, MA, USA
    Cancer Res 67:9084-8. 2007
    ..KIT activation levels in pediatric KIT-wild-type GISTs are comparable with those in KIT-mutant GISTs. Therapies that inhibit KIT activation, or crucial KIT signaling intermediates, should be explored in pediatric KIT-wild-type GIST...
  9. ncbi Modeling human osteosarcoma in the mouse: From bedside to bench
    Katherine A Janeway
    Department of Pediatric Oncology, Dana Farber Cancer Institute, Division of Hematology Oncology, Children s Hospital Boston, Harvard Medical School, 44 Binney St, Boston, MA 02115, USA
    Bone 47:859-65. 2010
    ....